2 results
Approved WMOCompleted
To obtain an estimate of the anterograde PCI success rate for patients with a confirmed target CTO in each treatment group and to explore safety and tolerability in these patients.
Approved WMORecruiting
The objective is to determine whether etidronate can halt or attenuate disease progression in patients with Fahr*s disease or syndrome.